A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Status:
Completed

Trial end date:
2020-08-10

Target enrollment:

Participant gender:

This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.

Phase 2

Poxel SA